BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 25691406)

  • 1. Craniofacial dysmorphology in 22q11.2 deletion syndrome by 3D laser surface imaging and geometric morphometrics: illuminating the developmental relationship to risk for psychosis.
    Prasad S; Katina S; Hennessy RJ; Murphy KC; Bowman AW; Waddington JL
    Am J Med Genet A; 2015 Mar; 167A(3):529-36. PubMed ID: 25691406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-dimensional laser surface imaging and geometric morphometrics resolve frontonasal dysmorphology in schizophrenia.
    Hennessy RJ; Baldwin PA; Browne DJ; Kinsella A; Waddington JL
    Biol Psychiatry; 2007 May; 61(10):1187-94. PubMed ID: 17217929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candidate genes and the behavioral phenotype in 22q11.2 deletion syndrome.
    Prasad SE; Howley S; Murphy KC
    Dev Disabil Res Rev; 2008; 14(1):26-34. PubMed ID: 18636634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neurocognitive and psychiatric management of the 22q11.2 deletion syndrome].
    Demily C; Rossi M; Schneider M; Edery P; Leleu A; d'Amato T; Franck N; Eliez S
    Encephale; 2015 Jun; 41(3):266-73. PubMed ID: 25523123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep psychophysiological phenotyping of adolescents and adults with 22q11.2 deletion syndrome: a multilevel approach to defining core disease processes.
    Parker DA; Cubells JF; Imes SL; Ruban GA; Henshey BT; Massa NM; Walker EF; Duncan EJ; Ousley OY
    BMC Psychiatry; 2023 Jun; 23(1):425. PubMed ID: 37312091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the 22q11.2 deletion syndrome and its relevance to schizophrenia.
    Van L; Boot E; Bassett AS
    Curr Opin Psychiatry; 2017 May; 30(3):191-196. PubMed ID: 28230630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling age-specific facial development in Williams-Beuren-, Noonan-, and 22q11.2 deletion syndromes in cohorts of Czech patients aged 3-18 years: A cross-sectional three-dimensional geometric morphometry analysis of their facial gestalt.
    Čaplovičová M; Moslerová V; Dupej J; Macek M; Zemková D; Hoffmannová E; Havlovicová M; Velemínská J
    Am J Med Genet A; 2018 Dec; 176(12):2604-2613. PubMed ID: 30380201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refining the resolution of craniofacial dysmorphology in bipolar disorder as an index of brain dysmorphogenesis.
    Katina S; Kelly BD; Rojas MA; Sukno FM; McDermott A; Hennessy RJ; Lane A; Whelan PF; Bowman AW; Waddington JL
    Psychiatry Res; 2020 Sep; 291():113243. PubMed ID: 32593068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontonasal dysmorphology in bipolar disorder by 3D laser surface imaging and geometric morphometrics: comparisons with schizophrenia.
    Hennessy RJ; Baldwin PA; Browne DJ; Kinsella A; Waddington JL
    Schizophr Res; 2010 Sep; 122(1-3):63-71. PubMed ID: 20554158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental trajectories of brain structure in adolescents with 22q11.2 deletion syndrome: a longitudinal study.
    Gothelf D; Penniman L; Gu E; Eliez S; Reiss AL
    Schizophr Res; 2007 Nov; 96(1-3):72-81. PubMed ID: 17804201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative subthreshold psychotic symptoms distinguish 22q11.2 deletion syndrome from other neurodevelopmental disorders: A two-site study.
    Mekori-Domachevsky E; Guri Y; Yi J; Weisman O; Calkins ME; Tang SX; Gross R; McDonald-McGinn DM; Emanuel BS; Zackai EH; Zalsman G; Weizman A; Gur RC; Gur RE; Gothelf D
    Schizophr Res; 2017 Oct; 188():42-49. PubMed ID: 28041919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shape-based classification of 3D facial data to support 22q11.2DS craniofacial research.
    Wilamowska K; Wu J; Heike C; Shapiro L
    J Digit Imaging; 2012 Jun; 25(3):400-8. PubMed ID: 22086243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comprehensive Craniofacial Study of 22q11.2 Deletion Syndrome.
    Lewyllie A; Roosenboom J; Indencleef K; Claes P; Swillen A; Devriendt K; Carels C; Cadenas De Llano-Pérula M; Willems G; Hens G; Verdonck A
    J Dent Res; 2017 Nov; 96(12):1386-1391. PubMed ID: 28732176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated Proinflammatory Markers in 22q11.2 Deletion Syndrome Are Associated With Psychosis and Cognitive Deficits.
    Mekori-Domachevsky E; Taler M; Shoenfeld Y; Gurevich M; Sonis P; Weisman O; Weizman A; Gothelf D
    J Clin Psychiatry; 2017; 78(9):e1219-e1225. PubMed ID: 29141125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Education and employment trajectories from childhood to adulthood in individuals with 22q11.2 deletion syndrome.
    Mosheva M; Pouillard V; Fishman Y; Dubourg L; Sofrin-Frumer D; Serur Y; Weizman A; Eliez S; Gothelf D; Schneider M
    Eur Child Adolesc Psychiatry; 2019 Jan; 28(1):31-42. PubMed ID: 29934817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological effects of COMT haplotypes and psychosis risk in 22q11.2 deletion syndrome.
    Gothelf D; Law AJ; Frisch A; Chen J; Zarchi O; Michaelovsky E; Ren-Patterson R; Lipska BK; Carmel M; Kolachana B; Weizman A; Weinberger DR
    Biol Psychiatry; 2014 Mar; 75(5):406-13. PubMed ID: 23992923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between neurodevelopmental genes, neuroanatomy, and ultra high risk symptoms of psychosis in 22q11.2 deletion syndrome.
    Thompson CA; Karelis J; Middleton FA; Gentile K; Coman IL; Radoeva PD; Mehta R; Fremont WP; Antshel KM; Faraone SV; Kates WR
    Am J Med Genet B Neuropsychiatr Genet; 2017 Apr; 174(3):295-314. PubMed ID: 28139055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further evidence for high rates of schizophrenia in 22q11.2 deletion syndrome.
    Monks S; Niarchou M; Davies AR; Walters JT; Williams N; Owen MJ; van den Bree MB; Murphy KC
    Schizophr Res; 2014 Mar; 153(1-3):231-6. PubMed ID: 24534796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Congenital diaphragmatic hernia in 22q11.2 deletion syndrome.
    Unolt M; DiCairano L; Schlechtweg K; Barry J; Howell L; Kasperski S; Nance M; Adzick NS; Zackai EH; McDonald-McGinn DM
    Am J Med Genet A; 2017 Jan; 173(1):135-142. PubMed ID: 27682988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predominant negative symptoms in 22q11.2 deletion syndrome and their associations with cognitive functioning and functional outcome.
    Schneider M; Van der Linden M; Menghetti S; Glaser B; Debbané M; Eliez S
    J Psychiatr Res; 2014 Jan; 48(1):86-93. PubMed ID: 24189154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.